GB2579480B - Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient - Google Patents

Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient Download PDF

Info

Publication number
GB2579480B
GB2579480B GB2001444.5A GB202001444A GB2579480B GB 2579480 B GB2579480 B GB 2579480B GB 202001444 A GB202001444 A GB 202001444A GB 2579480 B GB2579480 B GB 2579480B
Authority
GB
United Kingdom
Prior art keywords
preventing
composition
active ingredient
treating cancer
based derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2001444.5A
Other versions
GB202001444D0 (en
GB2579480A (en
Inventor
Yeon Ann Ji
Young Song Jie
Nam Ky-Youb
Ni Ryu Hwa
Jung In-Sung
Gu Hwang Sang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Inst Radiological & Medical Sciences
Korea Institute of Radiological and Medical Sciences
Original Assignee
Korea Inst Radiological & Medical Sciences
Korea Institute of Radiological and Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Radiological & Medical Sciences, Korea Institute of Radiological and Medical Sciences filed Critical Korea Inst Radiological & Medical Sciences
Publication of GB202001444D0 publication Critical patent/GB202001444D0/en
Publication of GB2579480A publication Critical patent/GB2579480A/en
Application granted granted Critical
Publication of GB2579480B publication Critical patent/GB2579480B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GB2001444.5A 2017-08-16 2018-02-28 Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient Active GB2579480B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170103561A KR101924801B1 (en) 2017-08-16 2017-08-16 Composition for preventing or treating cancer comprising triazolopyridine derivatives
PCT/KR2018/002502 WO2019035522A1 (en) 2017-08-16 2018-02-28 Composition for preventing or treating cancer containing triazolopyridine-based derivative as active ingredient

Publications (3)

Publication Number Publication Date
GB202001444D0 GB202001444D0 (en) 2020-03-18
GB2579480A GB2579480A (en) 2020-06-24
GB2579480B true GB2579480B (en) 2022-04-27

Family

ID=64668937

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2001444.5A Active GB2579480B (en) 2017-08-16 2018-02-28 Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient

Country Status (4)

Country Link
KR (1) KR101924801B1 (en)
DE (1) DE112018004197T5 (en)
GB (1) GB2579480B (en)
WO (1) WO2019035522A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200335182A1 (en) * 2019-04-16 2020-10-22 Uratim Ltd. Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
KR20230072623A (en) * 2021-11-18 2023-05-25 한국원자력의학원 Compound for inhibiting tankyrase and medical use thereof
KR20240121916A (en) * 2023-02-02 2024-08-12 한국원자력의학원 Composition for preventing or treating cancer containing aryl-piperidine derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040215A1 (en) * 2011-09-14 2013-03-21 Samumed, Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2015143380A1 (en) * 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025466B1 (en) 2009-12-31 2016-12-30 Хатчисон Медифарма Лимитед Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
JP6428114B2 (en) 2014-09-30 2018-11-28 ブラザー工業株式会社 Liquid consumption device
US10189785B2 (en) 2015-04-20 2019-01-29 Takeda Pharmaceuticals Company Limited Heterocyclic compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040215A1 (en) * 2011-09-14 2013-03-21 Samumed, Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2015143380A1 (en) * 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract Compound, STN express. RN 1223727-82-9 (14 May 2010) See the chemical formulas *
Chemical Abstract Compound, STN express. RN 1278246-01-7 (10 April 2011) See the chemical formulas *
Chemical Abstract Compound, STN express.RN 1293587-55-9 (12 May 2011) * See the chemical formulas. *

Also Published As

Publication number Publication date
WO2019035522A1 (en) 2019-02-21
GB202001444D0 (en) 2020-03-18
DE112018004197T5 (en) 2020-04-30
GB2579480A (en) 2020-06-24
KR101924801B1 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
PT3431105T (en) Medicinal composition for treating cancer
EP3895717C0 (en) Pharmaceutical composition for preventing or treating colorectal cancer, comprising weissella cibaria wikim28 as active ingredient
EP3263135A4 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
EP3473624A4 (en) Novel imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
HK1257615A1 (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3539951A4 (en) Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory diseases
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
ZA201803320B (en) Pharmaceutical compositions for treating pain
EP3701946A4 (en) Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
EP3329929A4 (en) Pharmaceutical composition for preventing or treating dry eyes
IL275525A (en) Pharmaceutical composition for the treatment of cancer
HK1243927A1 (en) Composition containing theasapogenol derivative as active ingredient
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
EP2982378A4 (en) Composition for preventing or treating sepsis or septic shock, comprising adk protein as active ingredient
SG11201704766UA (en) Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
EP3689355A4 (en) Pharmaceutical composition for preventing or treating liver cancer
EP3617211A4 (en) Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
IL269769B (en) Compounds, composition and uses thereof for treating cancer
EP3260121A4 (en) Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient
EP3687520A4 (en) Fixed dose combination formulations for treating pain
EP3542797A4 (en) Pharmaceutical composition for preventing or treating dyrk-related diseases, containing pyridine-based compound as active ingredient
EP3360581A4 (en) Pharmaceutical composition for preventing or treating cancer comprising inhibitor of plrg1 (pleiotropic regulator 1) as active ingredient

Legal Events

Date Code Title Description
789A Request for publication of translation (sect. 89(a)/1977)

Ref document number: 2019035522

Country of ref document: WO